Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 9:31 PM
Ignite Modification Date:
2025-12-24 @ 9:31 PM
NCT ID:
NCT00357032
Brief Summary:
This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory acute myeloid leukemia or older patients with newly diagnosed acute myeloid leukemia. PXD101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
Detailed Description:
PRIMARY OBJECTIVES:
I. Evaluate the response rate (complete response and partial response) in patients with acute myeloid leukemia treated with PXD101.
SECONDARY OBJECTIVES:
I. Evaluate the overall survival of these patients. II. Evaluate the duration of response in these patients. III. Evaluate the toxicity of this drug in these patients.
TERTIARY OBJECTIVES:
I. Evaluate molecular response to PXD101.
OUTLINE:
Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
Blood and bone marrow samples are obtained before and after study treatment for laboratory studies.
After completion of study treatment, patients are followed periodically for 1 year.
Study:
NCT00357032
Study Brief:
Protocol Section:
NCT00357032